Q2 Earnings Estimate for Longeveron Issued By HC Wainwright

Longeveron Inc. (NASDAQ:LGVN) – Research analysts at HC Wainwright lifted their Q2 2026 earnings estimates for Longeveron in a report released on Thursday, May 14th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their previous estimate of ($0.22). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($0.70) per share. HC Wainwright also issued estimates for Longeveron’s Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.74) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.48) EPS.

LGVN has been the topic of a number of other reports. Wall Street Zen cut shares of Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Longeveron in a research report on Tuesday, April 21st. Finally, Maxim Group cut shares of Longeveron from a “buy” rating to a “hold” rating in a research report on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.50.

Longeveron Price Performance

LGVN opened at $0.68 on Tuesday. The company’s 50 day simple moving average is $0.94 and its 200 day simple moving average is $0.72. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.88 and a current ratio of 3.88. Longeveron has a 1 year low of $0.48 and a 1 year high of $1.80. The stock has a market capitalization of $15.73 million, a PE ratio of -0.60 and a beta of -0.31.

Longeveron (NASDAQ:LGVN) last released its earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%. The business had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.33 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Longeveron stock. ADAR1 Capital Management LLC purchased a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned approximately 0.86% of Longeveron as of its most recent SEC filing. 10.01% of the stock is owned by hedge funds and other institutional investors.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.